FuzzyBot: Importing a new version from external source

2024-02-20T12:00:06Z

Importing a new version from external source

New page

One placebo-controlled, double-blind study was carried out at 18 different sites in Korea and 12 in Taiwan. Patients were above 20 and had type 2 diabetes for atlas 12 weeks. They were given an 8-week period to clear their systems of all other drugs (besides metformin). Patients received either 50 mg ipragliflozin or a placebo. The drugs were identical in all physical forms. The patients were prohibited from using any other anti diabetic drugs, other than metformin. The study ran for 24 weeks along with a 4-week follow-up period.
The standard deviation in [[Glycated hemoglobin|hemoglobin A<sub>1c</sub>]] were −0.94% and −0.47% in the ipragliflozin and placebo groups, respectively (between-group difference −0.46%, [[p-value|''p'']] <0.001). The changes in fasting plasma glucose and bodyweight were also significantly greater in the ipragliflozin group, with between-group differences of −14.1 mg/dL and −1.24 kg, respectively (both ''p'' <0.001). The most common adverse events that appeared were [[Upper respiratory tract infection|upper respiratory infection]]s and [[urinary tract infection]]s. From this it was concluded that ipragliflozin is both efficacious as well as safe.

Translations:Ipragliflozin/9/en - Revision history

FuzzyBot: Importing a new version from external source